PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

New clinical data with metformin therapy in patients with diabetes mellitus.

Abstract Metformin is widely used for treating patients with type 2 diabetes mellitus. Recently, new options of metformin therapy were highlighted by several clinical observations. Accordingly, the benefit of metformin for treating patients with type 1 diabetes was documented (as an add-on therapy to insulin, primarily in adult patients with the phenotype of type 2 diabetes). In addition, epidemiological studies unequivocally documented that metformin is associated with lower cancer morbidity and mortality rates in type 2 diabetic patients. Metformin was used in diabetic patients with systolic heart failure and the results proved to be promising in a clinical trial. The use of metformin in type 2 diabetic patients with insulin treatment can result in a decrease in insulin dose, an improvement in glycaemic control, a beneficial effect in weight changes and a decrease in risk of macrovascular complications. A late and prolonged beneficial effect of a former favourable metabolic milieu could be expected even in the subsequent years after terminating a randomized controlled trial with metformin. Although the new clinical observations should be considered encouraging, our clinical practice should strictly follow the current guidelines based on the label of metformin.
PMID
Related Publications

Oral antidiabetic agents: current role in type 2 diabetes mellitus.

Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial.

Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes.

Diabetes and cancer risk: oncologic considerations.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Authors

Mayor MeshTerms
Keywords
Journal Title orvosi hetilap
Publication Year Start
%A Jermendy, Gy?rgy
%T [New clinical data with metformin therapy in patients with diabetes mellitus].
%J Orvosi hetilap, vol. 151, no. 49, pp. 2025-2030
%D 12/2010
%V 151
%N 49
%M hun
%B Metformin is widely used for treating patients with type 2 diabetes mellitus. Recently, new options of metformin therapy were highlighted by several clinical observations. Accordingly, the benefit of metformin for treating patients with type 1 diabetes was documented (as an add-on therapy to insulin, primarily in adult patients with the phenotype of type 2 diabetes). In addition, epidemiological studies unequivocally documented that metformin is associated with lower cancer morbidity and mortality rates in type 2 diabetic patients. Metformin was used in diabetic patients with systolic heart failure and the results proved to be promising in a clinical trial. The use of metformin in type 2 diabetic patients with insulin treatment can result in a decrease in insulin dose, an improvement in glycaemic control, a beneficial effect in weight changes and a decrease in risk of macrovascular complications. A late and prolonged beneficial effect of a former favourable metabolic milieu could be expected even in the subsequent years after terminating a randomized controlled trial with metformin. Although the new clinical observations should be considered encouraging, our clinical practice should strictly follow the current guidelines based on the label of metformin.
%K Administration, Oral, Adult, Aged, Biomarkers, Clinical Trials as Topic, Diabetes Complications, Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Heart Failure, Humans, Hypoglycemic Agents, Incidence, Insulin, Metformin, Middle Aged, Neoplasms, Obesity, Randomized Controlled Trials as Topic
%P 2025
%L 2030
%Y 10.1556/OH.2010.29005
%W PHY
%G AUTHOR
%R 2010......151.2025J

@Article{Jermendy2010,
author="Jermendy, Gy{\"o}rgy",
title="[New clinical data with metformin therapy in patients with diabetes mellitus].",
journal="Orvosi hetilap",
year="2010",
month="Dec",
day="05",
volume="151",
number="49",
pages="2025--2030",
keywords="Administration, Oral",
keywords="Adult",
keywords="Aged",
keywords="Biomarkers",
keywords="Clinical Trials as Topic",
keywords="Diabetes Complications",
keywords="Diabetes Mellitus",
keywords="Diabetes Mellitus, Type 1",
keywords="Diabetes Mellitus, Type 2",
keywords="Heart Failure",
keywords="Humans",
keywords="Hypoglycemic Agents",
keywords="Incidence",
keywords="Insulin",
keywords="Metformin",
keywords="Middle Aged",
keywords="Neoplasms",
keywords="Obesity",
keywords="Randomized Controlled Trials as Topic",
abstract="Metformin is widely used for treating patients with type 2 diabetes mellitus. Recently, new options of metformin therapy were highlighted by several clinical observations. Accordingly, the benefit of metformin for treating patients with type 1 diabetes was documented (as an add-on therapy to insulin, primarily in adult patients with the phenotype of type 2 diabetes). In addition, epidemiological studies unequivocally documented that metformin is associated with lower cancer morbidity and mortality rates in type 2 diabetic patients. Metformin was used in diabetic patients with systolic heart failure and the results proved to be promising in a clinical trial. The use of metformin in type 2 diabetic patients with insulin treatment can result in a decrease in insulin dose, an improvement in glycaemic control, a beneficial effect in weight changes and a decrease in risk of macrovascular complications. A late and prolonged beneficial effect of a former favourable metabolic milieu could be expected even in the subsequent years after terminating a randomized controlled trial with metformin. Although the new clinical observations should be considered encouraging, our clinical practice should strictly follow the current guidelines based on the label of metformin.",
issn="0030-6002",
doi="10.1556/OH.2010.29005",
url="http://www.ncbi.nlm.nih.gov/pubmed/21106483",
language="hun"
}

%0 Journal Article
%T [New clinical data with metformin therapy in patients with diabetes mellitus].
%A Jermendy, Gy?rgy
%J Orvosi hetilap
%D 2010
%8 Dec 05
%V 151
%N 49
%@ 0030-6002
%G hun
%F Jermendy2010
%X Metformin is widely used for treating patients with type 2 diabetes mellitus. Recently, new options of metformin therapy were highlighted by several clinical observations. Accordingly, the benefit of metformin for treating patients with type 1 diabetes was documented (as an add-on therapy to insulin, primarily in adult patients with the phenotype of type 2 diabetes). In addition, epidemiological studies unequivocally documented that metformin is associated with lower cancer morbidity and mortality rates in type 2 diabetic patients. Metformin was used in diabetic patients with systolic heart failure and the results proved to be promising in a clinical trial. The use of metformin in type 2 diabetic patients with insulin treatment can result in a decrease in insulin dose, an improvement in glycaemic control, a beneficial effect in weight changes and a decrease in risk of macrovascular complications. A late and prolonged beneficial effect of a former favourable metabolic milieu could be expected even in the subsequent years after terminating a randomized controlled trial with metformin. Although the new clinical observations should be considered encouraging, our clinical practice should strictly follow the current guidelines based on the label of metformin.
%K Administration, Oral
%K Adult
%K Aged
%K Biomarkers
%K Clinical Trials as Topic
%K Diabetes Complications
%K Diabetes Mellitus
%K Diabetes Mellitus, Type 1
%K Diabetes Mellitus, Type 2
%K Heart Failure
%K Humans
%K Hypoglycemic Agents
%K Incidence
%K Insulin
%K Metformin
%K Middle Aged
%K Neoplasms
%K Obesity
%K Randomized Controlled Trials as Topic
%U http://dx.doi.org/10.1556/OH.2010.29005
%U http://www.ncbi.nlm.nih.gov/pubmed/21106483
%P 2025-2030

PT Journal
AU Jermendy, G
TI [New clinical data with metformin therapy in patients with diabetes mellitus].
SO Orvosi hetilap
JI Orv Hetil
PD Dec
PY 2010
BP 2025
EP 2030
VL 151
IS 49
DI 10.1556/OH.2010.29005
LA hun
DE Administration, Oral; Adult; Aged; Biomarkers; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Incidence; Insulin; Metformin; Middle Aged; Neoplasms; Obesity; Randomized Controlled Trials as Topic
AB Metformin is widely used for treating patients with type 2 diabetes mellitus. Recently, new options of metformin therapy were highlighted by several clinical observations. Accordingly, the benefit of metformin for treating patients with type 1 diabetes was documented (as an add-on therapy to insulin, primarily in adult patients with the phenotype of type 2 diabetes). In addition, epidemiological studies unequivocally documented that metformin is associated with lower cancer morbidity and mortality rates in type 2 diabetic patients. Metformin was used in diabetic patients with systolic heart failure and the results proved to be promising in a clinical trial. The use of metformin in type 2 diabetic patients with insulin treatment can result in a decrease in insulin dose, an improvement in glycaemic control, a beneficial effect in weight changes and a decrease in risk of macrovascular complications. A late and prolonged beneficial effect of a former favourable metabolic milieu could be expected even in the subsequent years after terminating a randomized controlled trial with metformin. Although the new clinical observations should be considered encouraging, our clinical practice should strictly follow the current guidelines based on the label of metformin.
ER

PMID- 21106483
OWN - NLM
STAT- MEDLINE
DA  - 20101125
DCOM- 20110324
LR  - 20151119
IS  - 0030-6002 (Print)
IS  - 0030-6002 (Linking)
VI  - 151
IP  - 49
DP  - 2010 Dec 5
TI  - [New clinical data with metformin therapy in patients with diabetes mellitus].
PG  - 2025-30
LID - 10.1556/OH.2010.29005 [doi]
AB  - Metformin is widely used for treating patients with type 2 diabetes mellitus.
      Recently, new options of metformin therapy were highlighted by several clinical
      observations. Accordingly, the benefit of metformin for treating patients with
      type 1 diabetes was documented (as an add-on therapy to insulin, primarily in
      adult patients with the phenotype of type 2 diabetes). In addition,
      epidemiological studies unequivocally documented that metformin is associated
      with lower cancer morbidity and mortality rates in type 2 diabetic patients.
      Metformin was used in diabetic patients with systolic heart failure and the
      results proved to be promising in a clinical trial. The use of metformin in type 
      2 diabetic patients with insulin treatment can result in a decrease in insulin
      dose, an improvement in glycaemic control, a beneficial effect in weight changes 
      and a decrease in risk of macrovascular complications. A late and prolonged
      beneficial effect of a former favourable metabolic milieu could be expected even 
      in the subsequent years after terminating a randomized controlled trial with
      metformin. Although the new clinical observations should be considered
      encouraging, our clinical practice should strictly follow the current guidelines 
      based on the label of metformin.
FAU - Jermendy, Gyorgy
AU  - Jermendy G
AD  - Bajcsy-Zsilinszky Korhaz III. Belgyogyaszati Osztaly Budapest Maglodi ut 89-91.
      1106. gyjermendy@mail.datanet.hu
LA  - hun
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Uj klinikai adatok a cukorbetegek metforminterapiajaval kapcsolatban.
PL  - Hungary
TA  - Orv Hetil
JT  - Orvosi hetilap
JID - 0376412
RN  - 0 (Biomarkers)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Biomarkers/blood
MH  - Clinical Trials as Topic
MH  - Diabetes Complications/blood/*epidemiology/mortality/physiopathology/*prevention 
      & control
MH  - Diabetes Mellitus/blood/*drug therapy/metabolism
MH  - Diabetes Mellitus, Type 1/complications/drug therapy
MH  - Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Heart Failure/epidemiology/*prevention & control
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/pharmacology/*therapeutic use
MH  - Incidence
MH  - Insulin/administration & dosage
MH  - Metformin/administration & dosage/pharmacology/*therapeutic use
MH  - Middle Aged
MH  - Neoplasms/epidemiology/etiology/*prevention & control
MH  - Obesity/*complications/physiopathology/*prevention & control
MH  - Randomized Controlled Trials as Topic
EDAT- 2010/11/26 06:00
MHDA- 2011/03/25 06:00
CRDT- 2010/11/26 06:00
AID - 3376H88Q88760028 [pii]
AID - 10.1556/OH.2010.29005 [doi]
PST - ppublish
SO  - Orv Hetil. 2010 Dec 5;151(49):2025-30. doi: 10.1556/OH.2010.29005.
TY  - JOUR
AU  - Jermendy, Gy?rgy
PY  - 2010/Dec/05
TI  - [New clinical data with metformin therapy in patients with diabetes mellitus].
T2  - Orv Hetil
JO  - Orvosi hetilap
SP  - 2025
EP  - 2030
VL  - 151
IS  - 49
KW  - Administration, Oral
KW  - Adult
KW  - Aged
KW  - Biomarkers
KW  - Clinical Trials as Topic
KW  - Diabetes Complications
KW  - Diabetes Mellitus
KW  - Diabetes Mellitus, Type 1
KW  - Diabetes Mellitus, Type 2
KW  - Heart Failure
KW  - Humans
KW  - Hypoglycemic Agents
KW  - Incidence
KW  - Insulin
KW  - Metformin
KW  - Middle Aged
KW  - Neoplasms
KW  - Obesity
KW  - Randomized Controlled Trials as Topic
N2  - Metformin is widely used for treating patients with type 2 diabetes mellitus. Recently, new options of metformin therapy were highlighted by several clinical observations. Accordingly, the benefit of metformin for treating patients with type 1 diabetes was documented (as an add-on therapy to insulin, primarily in adult patients with the phenotype of type 2 diabetes). In addition, epidemiological studies unequivocally documented that metformin is associated with lower cancer morbidity and mortality rates in type 2 diabetic patients. Metformin was used in diabetic patients with systolic heart failure and the results proved to be promising in a clinical trial. The use of metformin in type 2 diabetic patients with insulin treatment can result in a decrease in insulin dose, an improvement in glycaemic control, a beneficial effect in weight changes and a decrease in risk of macrovascular complications. A late and prolonged beneficial effect of a former favourable metabolic milieu could be expected even in the subsequent years after terminating a randomized controlled trial with metformin. Although the new clinical observations should be considered encouraging, our clinical practice should strictly follow the current guidelines based on the label of metformin.
SN  - 0030-6002
UR  - http://dx.doi.org/10.1556/OH.2010.29005
UR  - http://www.ncbi.nlm.nih.gov/pubmed/21106483
ID  - Jermendy2010
ER  - 
<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
<b:Source>
<b:Tag>Jermendy2010</b:Tag>
<b:SourceType>ArticleInAPeriodical</b:SourceType>
<b:Year>2010</b:Year>
<b:Month>Dec</b:Month>
<b:Day>5</b:Day>
<b:PeriodicalName>Orvosi hetilap</b:PeriodicalName>
<b:Volume>151</b:Volume>
<b:Issue>49</b:Issue>
<b:Pages>2025-2030</b:Pages>
<b:Author>
<b:Author><b:NameList>
<b:Person><b:Last>Jermendy</b:Last><b:First>Gy&#246;rgy</b:First></b:Person>
</b:NameList></b:Author>
</b:Author>
<b:Title>[New clinical data with metformin therapy in patients with diabetes mellitus].</b:Title>
 <b:ShortTitle>Orv Hetil</b:ShortTitle>
<b:Comments>Metformin is widely used for treating patients with type 2 diabetes mellitus. Recently, new options of metformin therapy were highlighted by several clinical observations. Accordingly, the benefit of metformin for treating patients with type 1 diabetes was documented (as an add-on therapy to insulin, primarily in adult patients with the phenotype of type 2 diabetes). In addition, epidemiological studies unequivocally documented that metformin is associated with lower cancer morbidity and mortality rates in type 2 diabetic patients. Metformin was used in diabetic patients with systolic heart failure and the results proved to be promising in a clinical trial. The use of metformin in type 2 diabetic patients with insulin treatment can result in a decrease in insulin dose, an improvement in glycaemic control, a beneficial effect in weight changes and a decrease in risk of macrovascular complications. A late and prolonged beneficial effect of a former favourable metabolic milieu could be expected even in the subsequent years after terminating a randomized controlled trial with metformin. Although the new clinical observations should be considered encouraging, our clinical practice should strictly follow the current guidelines based on the label of metformin.</b:Comments>
</b:Source>
</b:Sources>